Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis
Annals of Pharmacotherapy · 2024-10 · 58 (10) · 1054-1063
DOI: 10.1177/10600280231225770 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 23.01.2024. Verfasst von David Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC). Data sources: A PubMed search was conducted from inception to November 2023 using the keywords etrasimod, ulcerative colitis, and sphingosine-1-phosphate receptor modulator. Information was also obtained from published abstracts and package insert. Study selection and data extraction: Phase 2 and 3 studies plus relevant literature on etrasimod pharmacologic and clinical profile were reviewed. Data synthesis: Per ELEVATE, 2 phase 3 studies, a higher proportion of patients with moderately to severely active UC achieved clinical remission in the induction and maintenance phase with etrasimod compared with placebo. In addition, a higher proportion of patients achieved secondary endpoints of clinical response, endoscopic improvement-histologic remission, corticosteroid-free remission, and endoscopic improvement with etrasimod vs placebo. Common adverse events include anemia and headache. Relevance to patient care and clinical practice in comparison with existing drugs: Etrasimod is now the second orally administered sphingosine-1-phosphate modulator approved for UC, providing patients with additional treatment options. Efficacy rates of this treatment are in line with other UC medication options. Similar to other sphingosine-1-phosphate receptor modulators, various assessments are required at baseline and during treatment to ensure safe and appropriate use.
Conclusion
Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.
- Department of Pharmacy and Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: David Choi, Shubha Bhat
Zitieren
APA
Choi, D., Becker, M., Ivanov, M., & Bhat, S. (2024). Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Annals of Pharmacotherapy, 58(10), 1054-1063. https://doi.org/10.1177/10600280231225770
Vancouver
Choi D, Becker M, Ivanov M, Bhat S. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Annals of Pharmacotherapy. 2024;58(10):1054-1063. doi:10.1177/10600280231225770
BibTeX
@article{Choi2024,
author = {Choi, David and Becker, Michelle and Ivanov, Marina and Bhat, Shubha},
title = {Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis},
journal = {Annals of Pharmacotherapy},
year = {2024},
volume = {58},
number = {10},
pages = {1054--1063},
doi = {10.1177/10600280231225770}
}
EUVIMED